Holen Sie sich die Stockscreener-App
36.17
1.52%
-0.56
Handel nachbörslich:
36.58
0.41
+1.13%
Definium Therapeutics Inc Aktie (DFTX) Neueste Nachrichten
Form 144 DEFINIUM THERAPEUTICS For: 26 September - Investing.com India
Form 144 DEFINIUM THERAPEUTICS For: 25 September By Investing.com - Investing.com Nigeria
An officer sold 2,867 shares in the prior three months and lists 3,097 for sale at Definium Therapeutics (DFTX). - Stock Titan
After selling 13,008 shares in June, Definium Therapeutics (DFTX) officer Mark Sullivan proposes to sell 14,051. - Stock Titan
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression - Yahoo Finance
Definium Therapeutics, Inc. (DFTX) Options ChainYahoo Finance - Yahoo! Finance Canada
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Definium Therapeutics at TD Cowen summit: phase iii data lift dt120 - Investing.com
Definium Therapeutics reports 5.1‑point gap in second Phase 3 anxiety study - Mugglehead Investment Magazine
Definium Therapeutics, Inc. (DFTX) Latest Stock News & Headlines - Yahoo Finance
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $66 to $91 - Moomoo
Definium Therapeutics, Inc. (DFTX) latest stock news and headlines - Yahoo Finance Singapore
Definium Therapeutics, Inc. (NASDAQ: DFTX) Stock Price, News & Analysis - kalkine.ca
Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching - finance.yahoo.com
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX) - The Globe and Mail
Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study - finance.yahoo.com
Director at Definium Therapeutics (DFTX) now holds 22,296 shares - Stock Titan
Director boosts Definium (DFTX) stake with option exercise - Stock Titan
Definium Reports Second Phase III Success in Anxiety Disorder Program - The Globe and Mail
Definium Therapeutics (DFTX) Stock May Trade At A Premium Despite Phase 3 DT120 Results - Yahoo Finance
Why Definium Therapeutics (DFTX) Is Up 5.7% After Second Positive Phase 3 DT120 Anxiety Trial Result - Yahoo Finance
Definium Therapeutics (DFTX) After Its Phase 3 Win Still Looks Undervalued - Yahoo Finance
Definium Therapeutics Jumps 20% After Third Phase 3 Win for LSD-Based Anxiety Drug - finance.biggo.com
Stifel raises Definium Therapeutics stock price target on trial win By Investing.com - Investing.com Nigeria
Definium Therapeutics Rises as Investors Weigh Recent Regulatory Momentum and Near-Term Data Catalysts - quiverquant.com
Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy' - Benzinga
Definium (DFTX) CEO awarded 750,000 shares tied to clinical milestones - Stock Titan
Definium Therapeutics (DFTX) awards 125K performance shares tied to 2028 milestones - Stock Titan
Definium Therapeutics reports positive Phase 3 Panorama topline: DT120 ODT 100 µg shows -5.1 HAM-A benefit - TradingView
Definium Therapeutics (DFTX) posts third positive Phase 3 anxiety result ahead of planned NDA submission - Stock Titan
Definium Therapeutics stock jumps on positive trial results By Investing.com - Investing.com Nigeria
Definium Therapeutics stock jumps on positive trial results - Investing.com
S&P 500 Futures Decline in Premarket Trading; Definium Therapeutics, Primo Brands Lead - Barron's
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder - Business Wire
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 - Lelezard
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
Definium Therapeutics' Upcoming Phase 3 Data on DT120 to De-Risk Program, Back FDA Approval, RBC Says - marketscreener.com
DFTX Reiterated by RBC Capital -- Price Target Maintained at $66.00 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 - BioSpace
Definium Therapeutics (DFTX) Showcases Phase 3 Data Amid High Va - GuruFocus
DFTXDefinium Therapeutics Inc Revenue Breakdown - Finviz
Definium Therapeutics CEO Robert Barrow Sells 19,023 Shares Following 40,000-Share Award - Kalkine Media
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics Secures Second FDA Breakthrough Therapy Designation for DT120 in MDD - Minichart
Definium Therapeutics Gains FDA Breakthrough for Depression Drug - TipRanks
Definium Therapeutics (DFTX) Gains FDA Breakthrough Therapy Desi - GuruFocus
Definium Therapeutics receives FDA Breakthrough Therapy designation for DT120 ODT in MDD after positive Phase 3 - TradingView
Single LSD tablet in Definium Therapeutics (DFTX) trial shows 12-week benefit in major depression - Stock Titan
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results - Business Wire
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):